Bone Biologics Corp Files 8-K for Equity Sales
Ticker: BBLGW · Form: 8-K · Filed: Aug 2, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | 8-K |
| Filed Date | Aug 2, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001, $2.43, $0.125, $2.00, $20,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, definitive-agreement, financing
Related Tickers: BBLG
TL;DR
BBLG sold stock & warrants, raising cash. Details in 8-K.
AI Summary
On August 1, 2024, Bone Biologics Corporation entered into a material definitive agreement related to the sale of its common stock and warrants. The company also reported on unregistered sales of equity securities and other events, including financial statements and exhibits.
Why It Matters
This filing indicates Bone Biologics Corporation is raising capital through the sale of stock and warrants, which could impact its financial position and future operations.
Risk Assessment
Risk Level: medium — The filing details equity sales, which can dilute existing shareholders and signal potential financial needs.
Key Players & Entities
- Bone Biologics Corporation (company) — Registrant
- August 1, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Bone Biologics Corporation enter into?
The filing indicates a material definitive agreement related to the sale of common stock and warrants.
What is the accession number for this 8-K filing?
The accession number is 0001493152-24-029978.
What is the SIC code for Bone Biologics Corporation?
The SIC code is 3842 for ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES.
When was the earliest event reported in this filing?
The earliest event reported was on August 1, 2024.
What is the fiscal year end for Bone Biologics Corporation?
The fiscal year end for Bone Biologics Corporation is December 31.
Filing Stats: 1,646 words · 7 min read · ~5 pages · Grade level 13 · Accepted 2024-08-02 08:05:18
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark
- $2.43 — arch 6, 2024, with an exercise price of $2.43 per share, and which became exercisable
- $0.125 — ny's agreement to issue, for payment of $0.125 per New Warrant, (i) new unregistered f
- $2.00 — of Common Stock at an exercise price of $2.00 per share and (ii) new unregistered eig
- $20,000 — e Company also agreed to pay Wainwright $20,000 for non-accountable expenses, up to $50
- $50,000 — 000 for non-accountable expenses, up to $50,000 for legal fees and other out-of-pocket
- $3.35 — gent Warrants have an exercise price of $3.35 per share. The aggregate gross procee
- $2.1 m — the New Warrants, will be approximately $2.1 million, before deducting placement agent
Filing Documents
- form8-k.htm (8-K) — 60KB
- ex4-1.htm (EX-4.1) — 136KB
- ex4-2.htm (EX-4.2) — 129KB
- ex10-1.htm (EX-10.1) — 62KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 17KB
- 0001493152-24-029978.txt ( ) — 716KB
- bblg-20240801.xsd (EX-101.SCH) — 4KB
- bblg-20240801_def.xml (EX-101.DEF) — 26KB
- bblg-20240801_lab.xml (EX-101.LAB) — 36KB
- bblg-20240801_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: August 2, 2024 By: /s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer